ATE325889T1 - Screening-verfahren - Google Patents
Screening-verfahrenInfo
- Publication number
- ATE325889T1 ATE325889T1 AT01947681T AT01947681T ATE325889T1 AT E325889 T1 ATE325889 T1 AT E325889T1 AT 01947681 T AT01947681 T AT 01947681T AT 01947681 T AT01947681 T AT 01947681T AT E325889 T1 ATE325889 T1 AT E325889T1
- Authority
- AT
- Austria
- Prior art keywords
- cell
- apoptopic
- exposing
- identifying
- state
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 238000012216 screening Methods 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 abstract 1
- 230000026731 phosphorylation Effects 0.000 abstract 1
- 238000006366 phosphorylation reaction Methods 0.000 abstract 1
- 230000002269 spontaneous effect Effects 0.000 abstract 1
- 230000007704 transition Effects 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Ecology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0016692.6A GB0016692D0 (en) | 2000-07-07 | 2000-07-07 | Method |
| US25445900P | 2000-12-08 | 2000-12-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE325889T1 true ATE325889T1 (de) | 2006-06-15 |
Family
ID=26244614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01947681T ATE325889T1 (de) | 2000-07-07 | 2001-07-09 | Screening-verfahren |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1299558B1 (de) |
| AT (1) | ATE325889T1 (de) |
| AU (1) | AU2001269326A1 (de) |
| DE (1) | DE60119524T2 (de) |
| WO (1) | WO2002004657A2 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002352459A1 (en) * | 2001-12-20 | 2003-07-09 | Eirx Therapeutics Limited | Early stage redox-related apoptosis modulator-2 (esram-2) |
| EP1588163A2 (de) * | 2003-01-23 | 2005-10-26 | Eirx Therapeutics Ltd | Kinasen und g-protein gekoppelte rezeptoren die in der apoptose involviert sind |
| GB0305267D0 (en) * | 2003-03-07 | 2003-04-09 | Eirx Therapeutics Ltd | Proteins involved in apoptosis |
| WO2007002087A2 (en) * | 2005-06-20 | 2007-01-04 | Exelixis, Inc. | Cdc6s as modifiers of the pten/akt pathway and methods of use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR19990082168A (ko) * | 1996-12-02 | 1999-11-25 | 에가시라 구니오 | 글리오톡신 유도체 및 이를 함유하는 항암제 |
| NZ503417A (en) * | 1997-12-19 | 2002-12-20 | Warner Lambert Co | Use of SAG (sensitive to apoptosis gene) in protecting cells from apoptosis |
-
2001
- 2001-07-09 EP EP01947681A patent/EP1299558B1/de not_active Expired - Lifetime
- 2001-07-09 AT AT01947681T patent/ATE325889T1/de not_active IP Right Cessation
- 2001-07-09 DE DE60119524T patent/DE60119524T2/de not_active Expired - Fee Related
- 2001-07-09 WO PCT/GB2001/003101 patent/WO2002004657A2/en not_active Ceased
- 2001-07-09 AU AU2001269326A patent/AU2001269326A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE60119524D1 (de) | 2006-06-14 |
| WO2002004657A2 (en) | 2002-01-17 |
| WO2002004657A3 (en) | 2003-01-16 |
| EP1299558A2 (de) | 2003-04-09 |
| DE60119524T2 (de) | 2007-05-03 |
| EP1299558B1 (de) | 2006-05-10 |
| AU2001269326A1 (en) | 2002-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE269295T1 (de) | Btk inhibitoren und verfahren zur identifizierung und verwendung | |
| NO990338D0 (no) | Celleadhesjonsinhibitorer | |
| DK0906333T3 (da) | Substrater og inhibitorer for proteolytiske enzymer | |
| MXPA03011670A (es) | Sistema, metodo y producto de computadora para realizar confiabilidad predicable automatizada. | |
| ATE290208T1 (de) | Vorrichtung und verfahren zur ausführung elektrischer messungen an gegenständen | |
| ATE330032T1 (de) | Verfahren zur erhaltung der dns-integrität | |
| EA200001129A2 (ru) | Способ получения 4-карбоксиамино-2-замещенного-1,2,3,4-тетрагидрохинолина | |
| ATE444377T1 (de) | Nukleinsäurecharakterisierung | |
| DE69818278D1 (de) | Steroid sulfataseinhibitoren, verfahren zu ihrer herstellung und verwendung | |
| EP1509250A4 (de) | Verfahren, zusammensetzungen und herstellungsgegenstände zur modulierung des knochenwachstums | |
| DK1554638T3 (da) | Fremgangsmåde til at overvåge og analysere en proces | |
| ATE325889T1 (de) | Screening-verfahren | |
| ATE374939T1 (de) | Verfahren zur bestimmung einer restbetriebsdauer einer potentiometrischen messsonde, vorrichtung zur durchführung des verfahrens und ihre verwendung | |
| ATE483724T1 (de) | Verfahren zur erhöhung der ausbreitung von b- zellen | |
| DK1385993T3 (da) | Fremgangsmåde til detektering og behandling af tuberøs sclerose kompleksrelaterede lidelser | |
| DE50105206D1 (de) | Verfahren zum selektieren von inhibitoren für enzyme | |
| FI20022113A7 (fi) | Menetelmä ja järjestelmä väyläleveyden tunnistamiseksi, elektroniikkalaite ja oheislaite | |
| DE60216416D1 (de) | Verfahren zum nachweis von chloralhydrat in dichloressigsäure | |
| IL149404A0 (en) | METHODS AND COMPOSITIONS FOR MODULATING β-CATENIN PHOSPHORYLATION | |
| DE50305399D1 (de) | Verfahren zur Isolation des 20S Proteasoms, und Verfahren zur Identifikation von Inhibitoren des 20S und 26S Proteasoms | |
| ATE394480T1 (de) | Kristallstruktur der glutamatracemase (muri) | |
| NO20061215L (no) | Fremgangsmate for identifisering av IRS-proteinkinase-inbibitorer eller -agonister | |
| MXPA04001128A (es) | Metodo para identificar sustancias que afectan realmente condiciones inflamatorias. | |
| NO20050919L (no) | Fremgangsmate for identifisering av stoffer | |
| DE60232650D1 (de) | Peptiddeformylaseinhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |